Oxidative response of polymorphonuclear leucocytes to synovial fluids from patients with rheumatoid arthritis

B Dularay, J S Badesha, P A Dieppe, C J Elson

Abstract
Only a minority (7/35, 20%) of synovial fluids from patients with rheumatoid arthritis (RA) and none from patients with other arthritides stimulated the oxidative response of polymorphonuclear leucocytes (PMNs). Superoxide anion generation was measured by superoxide dismutase inhibitable reduction of cytochrome c. The same synovial fluids stimulated superoxide release by PMNs regardless of their source, though they elicited a greater response from RA synovial fluid PMNs than from either RA blood PMNs or blood PMNs from normal subjects. The remaining synovial fluids failed to stimulate any of the PMNs, though some (2/10) stimulated PMNs pretreated with cytochalasin B. The stimulatory activity was removed from RA synovial fluids by protein A-Sepharose and eluted with the void volume on gel chromatography. It is considered that immunoglobulin aggregates in some RA synovial fluids may stimulate the oxidative response of PMNs in the joint space but that most do not because these fluids contain either a specific inhibitor or immunoglobulin aggregates of an inappropriate type, or both.

Polymorphonuclear leucocytes (PMNs) are found in large numbers in the synovial fluids of patients with rheumatoid arthritis (RA) together with high concentrations of immunoglobulin aggregates. As aggregated immunoglobulins are known to stimulate PMNs to release superoxide anions in vitro it seems reasonable to suggest that the production of superoxide anions by PMNs will be stimulated by such aggregates in rheumatoid synovial fluids, and therefore be produced in vivo. Indeed, a number of authors have suggested that superoxide anions are produced by neutrophils in RA joints and contribute to tissue damage. There is little evidence that RA synovial fluids can stimulate PMNs to generate such products, however. Our report describes experiments which test the ability of RA synovial fluids to stimulate the release of superoxide anions from RA synovial fluid and RA blood PMNs as well as from blood PMNs from normal subjects.

Patients and methods

PATIENTS
Sixty patients (40 female (mean age 58); 20 male (mean age 57)) fulfilling the standard criteria for classical or definite RA were studied. They were receiving a variety of non-steroidal anti-inflammatory and slow acting antirheumatic drugs. Synovial fluids were obtained by therapeutic aspiration of inflamed joints which were free from bacterial infection. Samples were collected in 0·1 volume of acid citrate dextrose and centrifuged to remove the cells. The synovial fluids were divided into aliquots and stored at -70°C.

Synovial fluids were also obtained from four patients with osteoarthritis, four with psoriatic arthritis, and four with pyrophosphate arthropathy.

PMN PREPARATION
Peripheral blood from normal subjects or patients with RA was collected in 3·8% sodium citrate. The PMNs were isolated by sedimentation on dextran and density gradient separation in Percoll as described by Dooley and colleagues. This yielded a preparation of 98% PMNs as judged by Wright’s stain with <0·1% monocyte contamination as judged by non-specific esterase staining. For both blood and synovial fluid the yield of PMNs was between 55 and 75%. Polymorphonuclear leucocytes were isolated from synovial fluid in the same way omitting dextran sedimentation.

ASSAY OF SUPEROXIDE ANIONS
Superoxide anion generation was measured by superoxide dismutase inhibitable reduction of cytochrome c using a recording double beam spectrophotometer. Sample and reference cuvettes contained 106 PMNs and 1·2 mg cytochrome c (horse heart type III, Sigma) in 1 ml Hanks’s balanced salt solution (Gibco). The reference cuvette in addition contained 500 μg superoxide dismutase (bovine erythrocyte, Sigma). The stimulatory agent was added to both cuvettes and the reduction of cytochrome c monitored at 550 nm for 5–10 minutes. (The rates expressed, however, are maximal and occurred within the first two minutes of the reaction.) Nanomoles superoxide were calculated using an extinction coefficient of 21·1 mM/cm. The stimulatory agents used were synovial fluid (10–200 μL), N-formyl-methionyl-leucyl-phenylalanine (FMLP), and heat aggregated IgG. FMLP (Sigma) was dissolved in dimethyl sulphoxide and stored as a 1 mM stock solution at -70°C. IgG was prepared from human serum, adjusted to a protein concen-
tation of 30 mg/ml and heated at 63°C for 30 minutes.

In some experiments PMNs were pretreated with cytochalasin B. Polymorphonuclear leukocytes were incubated with 20 µg/ml cytochalasin B (Sigma; dissolved in dimethyl sulphoxide) for 10 minutes at room temperature before the ability of synovial fluids to stimulate their oxidative response was measured.

SEPHEROSE-PROTEIN A CHROMATOGRAPHY

IgG and IgG aggregates were removed from synovial fluid by affinity chromatography as described by Gouws [12]. Synovial fluid was incubated with hyaluronidase (Sigma; bovine, 100 units/ml of fluid) for 15 minutes at 37°C and centrifuged at 12,000 g for two minutes. The fluid was diluted 1 in 2 with phosphate buffered saline, pH 7.3, and applied to a column of Sepharose-protein A CL-4B (Sigma). The eluate was assayed for the presence of IgG with radial immunodiffusion kits (Serotec). As a control for non-specific removal of protein, synovial fluid was treated with Sepharose CL-4B (the matrix to which protein A is attached).

SEPARATION OF SYNOVIAL FLUID BY GEL CHROMATOGRAPHY

Synovial fluid was digested with hyaluronidase, diluted 1 to 1 with phosphate buffered saline and applied to a 2-6×100 cm column of ACA34 (LKB). The eluate was collected in 6 ml fractions at a flow of 5 ml/hour over 24 hours. The column had previously been calibrated using molecular weight markers in the range 14.5-150 kD and the void volume determined with dextran blue.

Results

OXIDATIVE RESPONSE OF PMNs TO SYNOVIAL FLUIDS

The oxidative response of normal blood PMNs to synovial fluids obtained from patients with RA or other arthritides was determined. In all, only 7/47 fluids tested stimulated the PMNs to release superoxide anions, though the test PMNs responded to stimulation with heat aggregated IgG and FMLP. All the stimulatory synovial fluids were from patients with RA, and fig 1 shows the oxidative response of the PMNs to six of these fluids. Each synovial fluid induced a response dependent on dose, which reached a maximum at 10-20%.

Polymorphonuclear leukocytes from RA synovial fluid may respond to synovial fluid constituents which fail to elicit responses from blood PMNs. Accordingly, a comparison was made between the response of paired RA synovial fluid and blood PMNs and normal blood PMNs to heterologous synovial fluid. The PMNs were stimulated with increasing concentrations of synovial fluids (2-5-25% v/v). Thirty five fluids (including five of the seven synovial fluids shown to stimulate normal blood PMNs) were tested on three paired RA blood and synovial fluid samples and on normal blood PMNs. As can be seen from table 1, five of the synovial fluids at one concentration (10% v/v) stimulated the release of superoxide anions from both blood and synovial fluid PMNs, and in each case the response of the synovial fluid PMNs was higher than that of the blood PMNs (RA and normal). Similar results were obtained at other concentrations. The remainder of the synovial fluids stimulated none of the PMNs.

In a further experiment the oxidative response of synovial fluid and paired blood PMNs from five patients with RA and of blood PMNs from 10 normal donors to one stimulatory synovial fluid (10% v/v) was measured. The mean (SD) response of the RA synovial fluid PMNs was 18.6 (4), of the paired blood PMNs 7.2 (1), and of the normal blood PMNs 6.8 (0.8) nanomoles superoxide anions/minute/10^6 PMNs. The oxidative response of RA synovial fluid and paired blood PMNs to 15 autologous synovial fluids was also tested. In all but two of these cases there was no measurable release of superoxide anions by the PMNs. Of the two, the response of the first patient's synovial fluid PMNs to their own fluid (10% v/v) was 5.4 (0.3) and of their blood PMNs 3.2 (0.8), and the response of the second patient's synovial fluid PMNs to their own fluid was 2.5 (0.5) and of their blood PMNs 2.8 (1.0) nanomoles superoxide anions/minute/10^6 PMNs. These two fluids, but none of the others, also stimulated heterologous RA and normal PMNs.

Table 1 Oxidative response of polymorphonuclear leukocytes (PMNs) from rheumatoid arthritis (RA) synovial fluid (SF), RA blood, and normal blood to heterologous RA syovial fluids. Results are the means (SD) of triplicate determinations

<table>
<thead>
<tr>
<th>Synovial fluid</th>
<th>Nanomoles superoxide/min/10^6 PMNs</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA SF PMNs</td>
<td>RA blood PMNs</td>
</tr>
<tr>
<td>1</td>
<td>15.0 (2.0)</td>
</tr>
<tr>
<td>2</td>
<td>29.2 (1.8)</td>
</tr>
<tr>
<td>3</td>
<td>12.4 (1.0)</td>
</tr>
<tr>
<td>4</td>
<td>9.0 (1.5)</td>
</tr>
<tr>
<td>5</td>
<td>11.0 (1.2)</td>
</tr>
</tbody>
</table>

*Synovial fluids from five patients with RA.
†NT=not tested.

Figure 1 Oxidative response of normal blood polymorphonuclear leukocytes (PMNs) to increasing concentrations of rheumatoid arthritis synovial fluids. The results are the mean (SD) of three measurements. Each symbol denotes one patient's synovial fluid.
EFFECT OF CYTOKINES ON OXIDATIVE RESPONSE TO SYNOVIAL FLUIDS

Cytokines are widely used to augment the response of PMNs to stimuli. It was wondered, therefore, whether the response of normal blood PMNs might be augmented by cytokines so that they would respond to low concentrations of stimulatory agents in synovial fluids. Normal blood PMNs were pretreated with cytokines and their oxidative response to RA synovial fluids, which had failed to stimulate the response of non-cytokine-treated PMNs, was measured. Two of the ten fluids tested stimulated superoxide production, and the results for these fluids are shown in Table 2. It can be seen that the effect was not linearly related to the concentration of synovial fluid.

IDENTITY OF STIMULATORY AGENT IN RA SYNOVIAL FLUID

As a first step towards determining the identity of the stimulatory agent in synovial fluid the response to heat (56°C for 30 minutes) and hyaluronidase treatment of synovial fluid stimulatory activity was studied, but no effect was seen. Thus, for example, the oxidative response of normal blood PMNs to one stimulatory synovial fluid was 9.5 nanomoles superoxide/minute/10^6 PMNs, 9.1 after heating, and 9.4 after hyaluronidase treatment and to a second stimulatory synovial fluid was 6.6 nanomoles superoxide/minute/10^6 PMNs, 6.4 after heating, and 6.6 after hyaluronidase digestion.

As immunoglobulin aggregates are potent stimulators of the oxidative response and are known to be present in RA synovial fluid the effect of removing such aggregates from synovial fluids on their stimulatory activity was measured. Three of the stimulatory synovial fluids were affinity chromatographed on either Sepharose-protein A or Sepharose alone and their ability to stimulate oxidative responses of normal blood PMNs tested. Table 3 shows that whereas most of the stimulatory activity of untreated synovial fluid was retained after Sepharose treatment, it was lost after affinity chromatography on Sepharose-protein A. To confirm that the test fluids respond to IgG aggregates they were stimulated with either heat aggregated or non-aggregated IgG. The mean (SD) response to heat aggregated IgG (75 μg/ml) was 2.7 (1.2) (range 0.9–2.8) but no response (<0.5 nanomoles superoxide anions/minute/10^6 PMNs) was elicited by non-aggregated IgG at the same or higher concentrations.

In another experiment synovial fluids were separated by gel chromatography and the fractions tested for their ability to stimulate PMN oxidative responses. Figure 2 shows the elution profile of one stimulatory synovial fluid. Only one fraction—namely, that corresponding to the void volume, stimulated superoxide release. Similar results were obtained with another stimulatory synovial fluid. By contrast, separation of non-stimulatory synovial fluids yielded no fraction which stimulated the generation of superoxide by PMNs.

Table 2 Oxidative response of cytochalasin B pretreated polymorphonuclear leucocytes (PMNs) to synovial fluids (SFs)

<table>
<thead>
<tr>
<th>Synovial fluid (%)</th>
<th>Nanomoles superoxide/min/10^6 PMNs</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF1</td>
<td>SF2</td>
</tr>
<tr>
<td>2.5</td>
<td>1.2</td>
</tr>
<tr>
<td>5.0</td>
<td>3.6</td>
</tr>
<tr>
<td>10.0</td>
<td>2.3</td>
</tr>
<tr>
<td>20.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>

*SF1, SF2=RRA synovial fluids. The results are the means of two experiments; each experiment was carried out in duplicate.

Table 3 Oxidative response of normal blood polymorphonuclear leucocytes (PMNs) to synovial fluids (SFs) before and after the specified treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Nanomoles superoxide/min/10^6 PMNs*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SF1</td>
</tr>
<tr>
<td>Whole SF</td>
<td>6.6</td>
</tr>
<tr>
<td>Sepharose-protein A</td>
<td>&lt;0.5</td>
</tr>
<tr>
<td>Sepharose CL-4B</td>
<td>4.2</td>
</tr>
</tbody>
</table>

*All values are the means of two experiments in which two measurements were made. Cells were stimulated with 10% (v/v) synovial fluid or synovial fluid treated as specified.

Discussion

The main finding reported here is that only a minority of rheumatoid synovial fluids, and none from patients with other arthritides, stimulate superoxide production by PMNs. These results do not necessarily disagree with previous work which showed that a much larger proportion of RA synovial fluids stimulated PMNs to produce a luminol enhanced chemiluminescence response. It is known that this response is dependent on a myeloperoxidase mediated reaction and not directly on superoxide release. Thus the activity observed by Gale and his colleagues was a measure of both degranulation and superoxide release. We have previously shown that many RA synovial fluids stimulate PMN degranulation, resulting in the release of myeloperoxidase, and presumably these fluids will also stimulate a chemiluminescence response. By contrast, the assay used here was a direct measure of superoxide release and would not detect the products of degranulation responses.

The occurrence of IgG aggregates in the
rheumatoid joint space is well reported. As aggregates of this type are potent stimuli of superoxide generation by PMNs in vitro we examined the possibility that the stimulatory activity of the synovial fluids was due to such aggregates. The removal of IgG, including IgG aggregates, from the synovial fluids led to loss of superoxide anion generating activity and as monomeric IgG was shown, by this and other studies, not to elicit superoxide anions from PMNs it seems reasonable to conclude that the loss of activity is due to the removal of IgG aggregates. Additionally, both stimulatory and non-stimulatory synovial fluids were fractionated according to size, but only stimulatory synovial fluids yielded a fraction that stimulated superoxide release. The stimulatory activity was restricted to a high molecular weight fraction, which again is consistent with the presence of IgG aggregates.

Immunoglobulin aggregates are found in most synovial fluids, yet only a fraction of the fluids stimulate superoxide release. There are at least two explanations for these observations. Firstly, the size and concentration of immunoglobulin aggregates are known to determine both the nature and the magnitude of the response elicited, with large insoluble immunoglobulin aggregates being potent stimulators of superoxide release. Secondly, synovial fluids contain an activity which specifically inhibits aggregated IgG stimulated superoxide production.

Agents arising from the interaction of superoxide radicals with cellular and synovial fluid components have been detected in synovial fluids. Thus it is perhaps surprising that only a small number of synovial fluids stimulate PMNs to release superoxide anions. It might be argued that the true number of stimulatory fluids is higher because PMNs pretreated with cytochalasin B did respond to some synovial fluids that failed to elicit a response from untreated PMNs (either normal or RA). It is known, however, that PMNs pretreated with cytochalasin B, unlike untreated PMNs, will respond to a variety of chemotactic agents, some of which are known to be present in synovial fluids. Another explanation is that only immunoglobulin aggregates deposited at tissue surfaces, but not those in synovial fluid, stimulate PMNs. Alternatively, immunoglobulin aggregates, able to stimulate PMNs to release superoxide, may not be continuously present in synovial fluids. Finally, superoxide anions may be generated by cells other than PMNs.

This work was supported by the MRC. B Dularay was in receipt of a SERC CASE studentship in collaboration with Roussel Laboratories.